ECSP10010005A - HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE - Google Patents

HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE

Info

Publication number
ECSP10010005A
ECSP10010005A EC2010010005A ECSP10010005A ECSP10010005A EC SP10010005 A ECSP10010005 A EC SP10010005A EC 2010010005 A EC2010010005 A EC 2010010005A EC SP10010005 A ECSP10010005 A EC SP10010005A EC SP10010005 A ECSP10010005 A EC SP10010005A
Authority
EC
Ecuador
Prior art keywords
human
antibody
disease
binding fragment
lymphoma
Prior art date
Application number
EC2010010005A
Other languages
Spanish (es)
Inventor
Sean Stevens
Joel H Martin
Li-Hsien Wang
Erin M Allison
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ECSP10010005A publication Critical patent/ECSP10010005A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

Un anticuerpo humano o un fragmento de unión al antígeno de un anticuerpo que se une específicamente al CD20 humano y que es capaz de inducir una citotoxicidad dependiente del complemento (CDC), y que es capaz de aumentar el tiempo de supervivencia sin síntomas entre aproximadamente 2 veces a aproximadamente 9 veces más o mayor, con relación a animales control tratados en un modelo de ratón del linfoma humano. El anticuerpo o su fragmento de unión al antígeno es útil es un método terapéutico para tratar una enfermedad o un trastorno mediado por CD20, como por ejemplo el linfoma no hodgkiniano, la artritis reumatoide, el lupus eritematoso sistémico, la enfermedad de Crohn, la leucemia linfocítica crónica, y las enfermedades inflamatorias.A human antibody or an antigen-binding fragment of an antibody that specifically binds to human CD20 and that is capable of inducing complement-dependent cytotoxicity (CDC), and that is capable of increasing the survival time without symptoms by approximately 2 times to about 9 times or more, relative to control animals treated in a mouse model of human lymphoma. The antibody or its antigen binding fragment is a therapeutic method for treating a disease or a disorder mediated by CD20, such as non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, leukemia chronic lymphocytic, and inflammatory diseases.

EC2010010005A 2007-07-31 2010-02-26 HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE ECSP10010005A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96281107P 2007-07-31 2007-07-31
US6799408P 2008-03-03 2008-03-03

Publications (1)

Publication Number Publication Date
ECSP10010005A true ECSP10010005A (en) 2010-03-31

Family

ID=40010730

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010005A ECSP10010005A (en) 2007-07-31 2010-02-26 HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD FOR USE

Country Status (28)

Country Link
US (3) US7879984B2 (en)
EP (1) EP2178916B1 (en)
JP (1) JP5588865B2 (en)
KR (1) KR101561020B1 (en)
CN (1) CN101809037B (en)
AU (1) AU2008282152B2 (en)
BR (1) BRPI0813985B1 (en)
CA (1) CA2695199C (en)
CO (1) CO6260105A2 (en)
CR (1) CR11243A (en)
DK (1) DK2178916T3 (en)
DO (1) DOP2010000037A (en)
EC (1) ECSP10010005A (en)
ES (1) ES2527297T3 (en)
GT (1) GT201000026A (en)
HN (1) HN2010000202A (en)
MA (1) MA31634B1 (en)
ME (1) ME00973B (en)
MX (1) MX2010000970A (en)
MY (1) MY147651A (en)
NI (1) NI201000016A (en)
NZ (1) NZ583019A (en)
PL (1) PL2178916T3 (en)
RU (1) RU2486205C2 (en)
SV (1) SV2010003468A (en)
TN (2) TN2010000054A1 (en)
WO (1) WO2009018411A1 (en)
ZA (1) ZA201000545B (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (en) 2009-07-08 2015-10-07 科马布有限公司 Animal Models and Therapeutic Molecules
NO2516457T3 (en) 2009-12-21 2018-08-11
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EA034778B1 (en) 2012-02-06 2020-03-19 Инхибркс, Инк. Cd47 antibodies and methods of use thereof
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JOP20200236A1 (en) * 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TW202423993A (en) * 2012-11-14 2024-06-16 美商再生元醫藥公司 Recombinant cell surface capture proteins
US20140140991A1 (en) * 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
HK1221168A1 (en) 2013-04-17 2017-05-26 西格诺药品有限公司 Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4- ylamino)phenyl)acrylamide for treating cancer
EP2986318A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
MX368286B (en) 2013-04-17 2019-09-27 Signal Pharm Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer.
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP2991651A1 (en) 2013-05-03 2016-03-09 Celgene Corporation Methods for treating cancer using combination therapy
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6478989B2 (en) * 2013-11-07 2019-03-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Combination therapy with anti-CD20 antibody and BTK inhibitor
TWI754319B (en) * 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for stress therapy
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
ES2809455T3 (en) 2014-11-17 2021-03-04 Regeneron Pharma Methods for tumor treatment using CD3xCD20 bispecific antibody
HUE051246T2 (en) 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunized shigatoxin subunit scaffolds and cell-targeting molecules containing them
CR20210429A (en) 2015-06-24 2021-09-24 Hoffmann La Roche TRANSFERRIN ANTI-RECEPTOR ANTIBODIES WITH DESIGNED AFFINITY (Divisional 2017-0562)
TWI870789B (en) 2015-08-04 2025-01-21 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
TWI819458B (en) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
HUE063377T2 (en) 2015-12-22 2024-01-28 Regeneron Pharma Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CA3203613A1 (en) * 2016-07-19 2018-01-25 Ibentrus, Inc. Bispecific proteins and methods for preparing same
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018118754A1 (en) * 2016-12-19 2018-06-28 Vanderbilt University Antibodies to human respiratory syncytial virus protein pre-fusion conformation and methods of use therefor
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
BR112020000127A2 (en) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. method for selecting a soy hydrolyzate, and, glycoprotein
CN111511762B (en) 2017-08-21 2025-05-06 天演药业公司 Anti-CD 137 molecules and uses thereof
BR112020010615A2 (en) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. protein pharmaceutical product, method and system for characterizing protein pharmaceutical product and low molecular weight impurities, method for producing an antibody, antibody, and, method and system uses
MX2020008095A (en) 2018-01-31 2020-09-24 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities.
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI786265B (en) 2018-02-02 2022-12-11 美商再生元醫藥公司 System and method for characterizing protein dimerization
KR20200127979A (en) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 Systems and methods for identifying viral contaminants
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3246952A1 (en) 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (en) 2018-05-10 2020-05-01 美商再生元醫藥公司 Systems and methods for quantifying and modifying protein viscosity
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN120795059A (en) 2018-08-27 2025-10-17 瑞泽恩制药公司 Use of raman spectroscopy in downstream purification
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
PT3844189T (en) 2018-08-31 2025-01-29 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
EP3852788A1 (en) 2018-09-17 2021-07-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
JP7687952B2 (en) * 2018-10-01 2025-06-03 アディセット セラピューティクス， インク． Compositions and methods relating to genetically engineered and non-genetically engineered gamma delta T cells for treating hematological tumors - Patents.com
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
PL3857237T3 (en) 2019-01-16 2023-07-10 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
AU2020275406A1 (en) 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
IL291020B2 (en) 2019-09-24 2025-04-01 Regeneron Pharma Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MY207613A (en) 2019-11-25 2025-03-06 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
CN121197633A (en) 2019-12-13 2025-12-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
CN113402612A (en) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
MX2023006077A (en) 2020-11-25 2023-06-06 Regeneron Pharma SUSTAINED RELEASE FORMULATIONS THROUGH NON-AQUEOUS MEMBRANE EMULSIFICATION.
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
TW202233827A (en) 2021-01-20 2022-09-01 美商再生元醫藥公司 Methods of improving protein titer in cell culture
AR125585A1 (en) 2021-03-03 2023-08-02 Regeneron Pharma SYSTEMS AND METHODS TO QUANTIFY AND MODIFY THE VISCOSITY OF PROTEINS
WO2022204282A1 (en) 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
BR112023024984A2 (en) 2021-06-01 2024-02-20 Regeneron Pharma AQUEOUS ELECTROPHORESIS SAMPLE BUFFER, METHOD FOR IDENTIFYING CONTAMINANTS OR IMPURITIES IN A PROTEIN DRUG SAMPLE, AND, KIT
TW202326138A (en) 2021-09-08 2023-07-01 美商再生元醫藥公司 A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
KR20240090312A (en) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. PH meter calibration and calibration
JP2024538673A (en) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド pH modeling and control system and method
MX2024005090A (en) 2021-10-26 2024-07-19 Regeneron Pharma SYSTEMS AND METHODS FOR GENERATING LABORATORY WATER AND DISTRIBUTING LABORATORY WATER AT DIFFERENT TEMPERATURES.
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
CN120418653A (en) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 Method and system for evaluating chromatographic column integrity
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
TW202508625A (en) 2023-05-01 2025-03-01 美商再生元醫藥公司 Multidose antibody drug products using phenol or benzyl alcohol
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
CN121925272A (en) 2023-09-29 2026-04-24 瑞泽恩制药公司 Lyophilization with controlled nucleation
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same
CN120647759A (en) * 2025-06-13 2025-09-16 郑州伊美诺生物技术有限公司 Aldosterone antigen binding molecules and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
MX9204374A (en) * 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (en) * 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PL195870B1 (en) * 1998-08-11 2007-11-30 Biogen Idec Inc Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
PT1176195E (en) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
ATE311199T1 (en) 1999-05-07 2005-12-15 Genentech Inc TREATMENT OF AUTOIMMUNE DISEASES WITH ANTAGONISTS THAT BIND SURFACE MARKERS OF B CELLS
ITMI991299A1 (en) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche USE OF ANTIBODIES AGAINST SURFACE ANTIGENS FOR THE TREATMENT OF DISEASE TRANSPLANT AGAINST GUESTS
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
RU2004127458A (en) * 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) ANTI-CD20 ANTIBODIES, THEIR HYBRID PROTEINS AND WAYS OF THEIR USE
US20030233797A1 (en) * 2002-06-25 2003-12-25 Anderson Dean A. Air handling system including shroud and grille, and method of use
KR20110017020A (en) * 2002-10-17 2011-02-18 젠맵 에이/에스 Human monoclonal antibodies against CD20
US6736137B1 (en) * 2003-02-28 2004-05-18 Tmr-A, Llc Protective hooded respirator with oral-nasal cup breathing interface
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
KR101351122B1 (en) 2003-05-09 2014-01-14 듀크 유니버시티 CD20-Specific Antibodies and Methods of Employing Same
AR044388A1 (en) * 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
DE10334793A1 (en) * 2003-07-30 2005-02-24 BSH Bosch und Siemens Hausgeräte GmbH Drying items in domestic dish washing machines has reversible hydroscopic material filled column through which recirculated air is driven by fan
BRPI0412629A (en) * 2003-08-29 2006-09-26 Genentech Inc Method of treating eye dysfunction in mammals
KR20060107555A (en) * 2003-12-19 2006-10-13 제넨테크, 인크. Detection of CD20 in Transplant Rejection
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
EP1773393A2 (en) * 2004-05-05 2007-04-18 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
CA2568336A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
RU2411956C2 (en) * 2004-10-05 2011-02-20 Дженентек, Инк. Method of treating vasculitis
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CN1331888C (en) * 2005-03-02 2007-08-15 中国人民解放军军事医学科学院生物工程研究所 Single strand double specificity anti-body resisting human B cell leucoma
AR053579A1 (en) * 2005-04-15 2007-05-09 Genentech Inc TREATMENT OF INTESTINAL INFLAMMATORY DISEASE (IBD)
WO2006116369A2 (en) * 2005-04-22 2006-11-02 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
KR20080031001A (en) 2005-06-02 2008-04-07 아스트라제네카 아베 Antibodies to CD20 and Their Uses

Also Published As

Publication number Publication date
TN2010000054A1 (en) 2011-09-26
US7879984B2 (en) 2011-02-01
CO6260105A2 (en) 2011-03-22
CR11243A (en) 2010-05-19
ES2527297T3 (en) 2015-01-22
RU2010107175A (en) 2011-09-10
US20110081681A1 (en) 2011-04-07
CA2695199A1 (en) 2009-02-05
RU2486205C2 (en) 2013-06-27
GT201000026A (en) 2012-04-23
BRPI0813985B1 (en) 2022-05-10
ZA201000545B (en) 2011-04-28
MX2010000970A (en) 2010-03-09
JP5588865B2 (en) 2014-09-10
KR20100057012A (en) 2010-05-28
CN101809037B (en) 2014-01-15
CN101809037A (en) 2010-08-18
SV2010003468A (en) 2010-08-10
CA2695199C (en) 2016-07-19
AU2008282152A1 (en) 2009-02-05
US8329181B2 (en) 2012-12-11
DOP2010000037A (en) 2017-07-31
US8097713B2 (en) 2012-01-17
NZ583019A (en) 2011-05-27
HN2010000202A (en) 2012-08-15
NI201000016A (en) 2010-07-27
US20120100145A1 (en) 2012-04-26
MA31634B1 (en) 2010-08-02
US20090035322A1 (en) 2009-02-05
HK1141811A1 (en) 2010-11-19
BRPI0813985A2 (en) 2017-08-01
ME00973B (en) 2012-06-20
AU2008282152B2 (en) 2013-12-19
WO2009018411A1 (en) 2009-02-05
DK2178916T3 (en) 2015-01-12
TN2010000056A1 (en) 2011-09-26
JP2010535033A (en) 2010-11-18
MY147651A (en) 2012-12-31
EP2178916B1 (en) 2014-12-17
KR101561020B1 (en) 2015-10-26
EP2178916A1 (en) 2010-04-28
PL2178916T3 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
NI201000016A (en) HUMAN ANTIBODIES AGAINST HUMAN CD20 AND METHOD OF USING THEM.
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
JOP20200161B1 (en) Monoclonal antibodies and their uses
PE20180499A1 (en) UNION TO TAU ANTIBODIES
MX388710B (en) COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS FOR THEIR USE.
WO2020121195A8 (en) Trem2 antibodies and uses thereof
GT200900002A (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
EA201891495A1 (en) BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EA201890162A1 (en) ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY
EA201891966A1 (en) MOLECULES ASSOCIATING BCMA AND METHODS OF THEIR APPLICATION
PE20141166A1 (en) ANTI-ANGPTL3 ANTIBODIES AND USES OF THEM
AR096617A1 (en) ANTI-TWEAKR ANTIBODIES AND THEIR USES
EA201890175A1 (en) ANTIBODIES TO CD40
GT201300149A (en) PROTEINS OF UNION TO TNF-A
EA201692458A1 (en) ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2015013194A (en) TREATMENT OF CANCER USING A HUMANIZED ANTI-CD19 ANTIGEN CHEMICAL RECEPTOR.
MX2020009260A (en) Use of semaphorin-4d binding molecules for treating neurodegenerative disorders.
PE20141045A1 (en) BCMA BINDING PROTEINS (CD269 / TNFRSF17)
UA123202C2 (en) ANTIBODY TO TAU-PROTEIN AND ITS APPLICATION
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EA202092302A1 (en) ANTIBODIES TO TREM-1 AND THEIR APPLICATIONS
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
JP2017518260A5 (en)
EA201991203A1 (en) METHODS FOR TREATING ANGIBILITY OBSTRUCTION FOR ANGPTL8
EA201891499A1 (en) CHEMICAL DOG ANTI-CD20 ANTIBODY